Immuno-Oncology | Specialty

Dr. Loi on the Association Between TILs and Trastuzumab

December 11th 2013

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

Hematologic Immunotherapy Breaks New Ground in Established Field

December 6th 2013

Although immunotherapy advances in solid tumors have captured much attention in recent years, therapeutic strategies that enable the patient's own immune system to battle cancer cells have long been integrated into the treatment of patients with hematologic malignancies.

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

December 5th 2013

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

Dr. Balar on Immunotherapy in Bladder Cancer

November 25th 2013

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.

Novel Vaccine Induces Durable Remissions in Patients With Advanced Lymphoma

November 25th 2013

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20th 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Treating Renal Cell Carcinoma in 2013: An Interview With Sumanta Kumar Pal, MD

November 19th 2013

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical Research

November 19th 2013

The Malignant Melanoma Program at Wake Forest Baptist Health employs a multidisciplinary approach for the management of patients with all stages of this disease. The goals of the program are centered on unequivocal excellence in all areas of care for patients with malignant melanoma.

Dr. Galsky on Ipilimumab in Bladder Cancer

November 15th 2013

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.

Promising Immune Activation Found in mRCC for AGS-003

November 14th 2013

The investigational autologous dendritic cell vaccine AGS-003 successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma

PD-1 and PD-L1 Inhibitors Expected to 'Change the Landscape' of Lung Cancer Treatment

November 11th 2013

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

Targeted Therapies Explored in Small Cell Lung Cancer

November 11th 2013

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

Dr. Sondak on Ipilimumab in Melanoma

November 7th 2013

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

Dr. Weber on Immunologic Activities of Targeted Agents

November 5th 2013

Jeffrey S. Weber, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the immunologic activities of targeted agents for the treatment of melanoma.

Dr. Rosenberg Accepts His "Giants of Cancer Care" Award

November 5th 2013

Steven A. Rosenberg, MD, PhD, chief of surgery, National Cancer Institute, professor of surgery, Uniformed Services University of Health Sciences, George Washington University School of Medicine and Health Sciences, accepts the "Giants of Cancer Care" Award for his work in immunotherapy.

Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer

November 5th 2013

The notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.

Dr. Kudchadkar on Combining Therapies for Melanoma

November 1st 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the potential for combining therapies for the treatment of melanoma.

Dr. Brahmer on Distinguishing Between Response and Growth

October 30th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses how physicians distinguish between a response to an immunotherapy and cancer growth.

Nivolumab Survival Benefit Extended in Updated NSCLC Results

October 28th 2013

The PD-1 blocking antibody nivolumab continues to demonstrate sustained clinical activity in previously treated patients with advanced non-small cell lung cancer.

Dr. Hamid Discusses Melanoma Treatment

October 28th 2013

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.